NewYorkBIO appointed the 2026 Board of Directors representing various sectors and share a commitment to advancing the growth of New York’s statewide life science industry.
The new class of leaders includes Andrew Lam of Ally Bridge Group,Theresa Mazzullo of Excell Partners, Monica Shaw of Bristol Myers Squibb and Julia Nanyi Zhao, PhD of BioLabs@NYU.
The following board members were reelected to serve another three-year term: Rana Al-Hallaq llaq of Pfizer Ventures, Matt Badalucco of Merck, Dawn Bell of Kardigan.Bio, Lis Leiderman, MD,
Robert Van Nostrand a Veteran Biotech CFO, Manan Shah of 1619 Advisors and Alan Tamarelli of Cooley LLP.

Authored by Andre O. Hudson, Dean of the College of Science, Professor of Biochemistry, Rochester Institute of Technology, this article underscores both the urgency of the antibiotic resistance crisis and the innovations that offer real hope from faster diagnostics and novel therapeutic approaches to stronger policies and improved stewardship.

Nilo Therapeutics, an early-stage biotech company developing groundbreaking therapies for autoimmune and inflammatory diseases, was selected for its bold innovation, commitment to patient-centered science, and deep roots in the New York community. As the 2025 winner, Nilo received a $15,000 cash prize in recognition of its impact and continued potential to shape the future of health and biotechnology in the city.